Paper16636248
MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.
Pope WB and 4 others. Neurology, 2006. Cited by 230 papers, by iCite.
Cite this record
ConductScience Library. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Papers, record 16636248. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/16636248
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Monoclonal | Major topic |
| Glioma | Major topic |
| Adult | |
| Aged | |
| Antibodies, Monoclonal, Humanized | |
| Bevacizumab | |
| Camptothecin | |
| Carboplatin | |
| Drug Therapy, Combination | |
| Etoposide | |
| Female | |
| Humans | |
| Irinotecan | |
| Magnetic Resonance Imaging | |
| Male | |
| Middle Aged | |
| Neoplasm Recurrence, Local | |
| Vascular Endothelial Growth Factor A |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 17159134 | MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. | https://conductscience.org/library/papers/17159134 |
Source PubMed
Cited by129
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 230 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42199889 | Case Report: Beyond two years: a neurosurgical review of prolonged survival and late recurrence in IDH-wildtype GBM. | Front Surg | 2026 | https://conductscience.org/library/papers/42199889 | PubMed |
| 39330753 | Magnetic Resonance-Guided Cancer Therapy Radiomics and Machine Learning Models for Response Prediction. | Tomography | 2024 | https://conductscience.org/library/papers/39330753 | PubMed |
| 39162874 | Is add-on Bevacizumab therapy to Temozolomide and radiotherapy associated with clinical utility for newly diagnosed Glioblastoma? A systematic review and meta-analysis. | Neurosurg Rev | 2024 | https://conductscience.org/library/papers/39162874 | PubMed |
| 38596714 | Antiangiogenic exclusion rules in glioma trials: Historical perspectives and guidance for future trial design. | Neurooncol Adv | 2024 | https://conductscience.org/library/papers/38596714 | PubMed |
| 38406805 | First-line chemoimmunotherapy and immunotherapy in patients with non-small cell lung cancer and brain metastases: a registry study. | Front Oncol | 2024 | https://conductscience.org/library/papers/38406805 | PubMed |
| 35419519 | The impact of different volumetric thresholds to determine progressive disease in patients with recurrent glioblastoma treated with bevacizumab. | Neurooncol Adv | 2022 | https://conductscience.org/library/papers/35419519 | PubMed |
| 34047805 | Longitudinal structural and perfusion MRI enhanced by machine learning outperforms standalone modalities and radiological expertise in high-grade glioma surveillance. | Neuroradiology | 2021 | https://conductscience.org/library/papers/34047805 | PubMed |
| 33828976 | Seizures, Edema, Thrombosis, and Hemorrhages: An Update Review on the Medical Management of Gliomas. | Front Oncol | 2021 | https://conductscience.org/library/papers/33828976 | PubMed |
| 32957732 | Aptamer-Based In Vivo Therapeutic Targeting of Glioblastoma. | Molecules | 2020 | https://conductscience.org/library/papers/32957732 | PubMed |
| 32524791 | Radiological Recurrence Patterns after Bevacizumab Treatment of Recurrent High-Grade Glioma: A Systematic Review and Meta-Analysis. | Korean J Radiol | 2020 | https://conductscience.org/library/papers/32524791 | PubMed |
| 32152825 | Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma. | Mol Neurobiol | 2020 | https://conductscience.org/library/papers/32152825 | PubMed |
| 32076934 | Super selective intra-arterial cerebral infusion of modern chemotherapeutics after blood-brain barrier disruption: where are we now, and where we are going. | J Neurooncol | 2020 | https://conductscience.org/library/papers/32076934 | PubMed |
| 31689995 | Progression-Free but No Overall Survival Benefit for Adult Patients with Bevacizumab Therapy for the Treatment of Newly Diagnosed Glioblastoma: A Systematic Review and Meta-Analysis. | Cancers (Basel) | 2019 | https://conductscience.org/library/papers/31689995 | PubMed |
| 29779086 | Retrospective study of nivolumab for patients with recurrent high grade gliomas. | J Neurooncol | 2018 | https://conductscience.org/library/papers/29779086 | PubMed |
| 29660005 | Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma. | Neuro Oncol | 2018 | https://conductscience.org/library/papers/29660005 | PubMed |
| 29622553 | Edge Contrast of the FLAIR Hyperintense Region Predicts Survival in Patients with High-Grade Gliomas following Treatment with Bevacizumab. | AJNR Am J Neuroradiol | 2018 | https://conductscience.org/library/papers/29622553 | PubMed |
| 29040703 | Evidence and context of use for contrast enhancement as a surrogate of disease burden and treatment response in malignant glioma. | Neuro Oncol | 2018 | https://conductscience.org/library/papers/29040703 | PubMed |
| 28927109 | Disease progression patterns of bevacizumab responders with recurrent malignant gliomas. | Oncol Lett | 2017 | https://conductscience.org/library/papers/28927109 | PubMed |
| 28819189 | Vascular Hysteresis Loops and Vascular Architecture Mapping in Patients with Glioblastoma treated with Antiangiogenic Therapy. | Sci Rep | 2017 | https://conductscience.org/library/papers/28819189 | PubMed |
| 28516072 | Bevacizumab in Recurrent Glioma: Patterns of Treatment Failure and Implications. | Brain Tumor Res Treat | 2017 | https://conductscience.org/library/papers/28516072 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/16636248
GET https://conductscience.org/api/papers/v1/16636248/cited_by?page=2